Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry David Fiorentino, MD, PhD, Vincent Ho, MD, Mark.

Slides:

Advertisements

Similar presentations

Use of the diagonal mattress suture to prevent dog-ear formation

Advertisements

Surgical margins for melanoma in situ

Clavi syphilitici–an unusual presentation of syphilis

Optimal time to provide skin cancer and photoprotection education to pediatric solid organ transplant recipients Lily Chen, BA, Feng Gao, MD, PhD, MPH,

Tsung-Yu Tsai, MD, Yu-Chen Huang, MD

Acute transverse myelitis during treatment with etanercept for severe plaque psoriasis Juan Escalas, PhD, MD, Nicole Knöpfel, MD, Ana Martin-Santiago,

A girl with a solitary red bulla

Facial adenocarcinoma treated with intra-arterial chemotherapy

Striking leflunomide efficacy against refractory cutaneous sarcoidosis

Yul W. Yang, MD, PhD, David J. DiCaudo, MD

Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients Lucy Y. Liu, BA, Brittany.

Allison Hanlon, MD, PhD, June Kim, MD, David J. Leffell, MD

Image registration of sequential transparent photographs to localize and detect new versus recurrent tumors in dermatologic and Mohs micrographic surgery

Psoriasis and suicidality: A systematic review and meta-analysis

Baldness reversed by chemotherapy

Efficacy of simvastatin in plaque psoriasis: A pilot study

Type I pityriasis rubra pilaris treated with tumor necrosis factor inhibitors, ustekinumab, or secukinumab: A review Nolan J. Maloney, BS, Lisa D. Hisaw,

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD

Surveillance and assessment of occupational dermatitis using Rhode Island workers' compensation data 1998 to 2002 Irwin B. Horwitz, PhD, Brian P. McCall,

Vaishali Patel, PharmD, Elizabeth J. Horn, PhD, Steve J

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study Hsien-Yi Chiu, MD, Tsen-Fang.

JAK inhibitors in dermatology: The promise of a new drug class

Sara A. Farber, BA, Sara Samimi, MD, Misha Rosenbach, MD

David T. Pompei, Pharm D, Kameron S. Rezzadeh, BS, Kate V

Katherine E. Brick, BS, Robert H. Cook-Norris, MD, David A

The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis Alan Menter, MD, Jennifer C. Cather, MD, Diane.

Dermatology physician extenders: A new risk factor?

Pharmacy costs of specialty medications for plaque psoriasis in the United States Eric J. Yang, BS, Kristen M. Beck, MD, Sahil Sekhon, MD, Tina Bhutani,

Smoking and risk of psoriasis: A nationwide cohort study

A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis Lorinda Chung, MD, David Fiorentino,

Applying for dermatology residency is difficult and expensive

Treatment of toxic epidermal necrolysis in North America

Infliximab treatment for severe psoriasis in a patient with active hepatitis B virus infection Alberto Conde-Taboada, MD, Javier Pedraz Muñoz, MD, Lucía.

Characterization of disease burden, comorbidities, and treatment use in a large, US- based cohort: Results from the Corrona Psoriasis Registry Bruce Strober,

Alopecia areata Journal of the American Academy of Dermatology

Vitamin D deficiency in patients with chronic and acute urticaria: A systematic review and meta-analysis Tsung-Yu Tsai, MD, Yu-Chen Huang, MD Journal.

Successful use of a modified Goeckerman regimen in the treatment of generalized prurigo nodularis Eric Sorenson, AB, Ethan Levin, MD, John Koo, MD, Timothy.

A survey-based study on nail examinations at an American Academy of Dermatology free skin cancer screening Dayoung Ko, BS, Shari R. Lipner, MD, PhD

Treatment of psoriasis vulgaris using low-dose naltrexone

Partik Singh, BA, Jonathan I. Silverberg, MD, MPH, PhD

Management of psoriasis vulgaris and multiple sclerosis with fumaric acid Spyridon Gkalpakiotis, MD, PhD, Petr Arenberger, MD, PhD, DSc, Prof, Petra Gkalpakioti,

Infectious rash after riding elephants

Gwanghyun Jo, MD, Je-Ho Mun, MD, PhD

Robert Kantor, BS, Prarthana Dalal, BS, David Cella, PhD, Jonathan I

Lip edema Journal of the American Academy of Dermatology

Alan Menter, MD, Chair, Alice Gottlieb, MD, PhD, Steven R

Solomon Shockman, MD, Lauren Krug, MD, Nektarios Lountzis, MD

Isotretinoin for high-grade or refractory epidermal growth factor receptor inhibitor-related acneiform papulopustular eruptions Herbert C. Chiang, MD,

Anjali Shroff, MD, Emma Guttman-Yassky, MD, PhD JAAD Case Reports

Medicaid acceptance among pediatric dermatologists

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept-

Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3.

Increased risks of autoimmune rheumatic diseases in patients with psoriasis: A nationwide population-based study Hyun Jeong Ju, MD, Ki-Jo Kim, MD, PhD,

Role of graft-versus-host disease in the development of secondary skin cancers in hematopoietic stem cell transplant recipients: A meta-analysis Pooja.

Tsung-Yu Tsai, MD, Yu-Chen Huang, MD

Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1,

Modification of the nail psoriasis severity index

Tofacitinib therapy for children with severe alopecia areata

Derek Y. Hsu, BA, Kenneth Gordon, MD, Jonathan I

Jose Fernández-Vozmediano, PhD, Jose Armario-Hita, MD

Minimal improvements in the global burden of skin disease from 1990 to 2013 Jessica Mounessa, Taylor Braunberger, MD, Cory A. Dunnick, MD, Robert P. Dellavalle,

Comparative effectiveness of biologic agents for the treatment of psoriasis in a real- world setting: Results from a large, prospective, observational.

Eyebrow transplantation: Alternative body sites as a donor source

Gaps in pain management in dermatology: A needs assessment from Canada

Numerous hyperpigmented macules of the oral mucosa

Brittany G. Craiglow, MD, Brett A. King, MD, PhD

Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani Erwin Suys, MD Journal of the American Academy.

Reporting of harm and safety results in randomized controlled trials published in 5 dermatology journals Cynthia Haddad, PharmD, MSc, Odette Berline.

Daily oxymetazoline cream demonstrates high and sustained efficacy in patients with persistent erythema of rosacea through 52 weeks of treatment Michael.

Stuart M. Goldsmith, MD, Armand B. Cognetta, MD

Presentation transcript:

Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry David Fiorentino, MD, PhD, Vincent Ho, MD, Mark G. Lebwohl, MD, Luiz Leite, MD, Lori Hopkins, PharmD, Claudia Galindo, MD, Kavitha Goyal, MD, Wayne Langholff, PhD, Steven Fakharzadeh, MD, PhD, Bhaskar Srivastava, MD, PhD, Richard G. Langley, MD Journal of the American Academy of Dermatology Volume 77, Issue 5, Pages 845-854.e5 (November 2017) DOI: 10.1016/j.jaad.2017.07.013 Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions

Fig 1 Psoriasis. Disposition of malignancy cases and matched controls. PSOLAR, Psoriasis Longitudinal Assessment and Registry. Journal of the American Academy of Dermatology 2017 77, 845-854.e5DOI: (10.1016/j.jaad.2017.07.013) Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions

Fig 2 Psoriasis. Adjusted odds ratios (ORs) (95% confidence intervals [CIs]) of overall malignancies associated with duration of therapy with methotrexate, tumor necrosis factor-α (TNF-α) inhibitors, or ustekinumab within 12 months of exposure (primary analysis) (A), 6 months of exposure (sensitivity analysis) (B), and 24 months of exposure (sensitivity analysis) (C). *The P value comparing malignancy cases with matched controls was significant for TNF-α inhibitor treatment within the 12-month (P = .012), 6-month (P = .028), and 24-month (P = .012) exposure periods. Journal of the American Academy of Dermatology 2017 77, 845-854.e5DOI: (10.1016/j.jaad.2017.07.013) Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions

Supplemental Fig 1 Psoriasis. Adjusted odds ratios (ORs) (95% confidence intervals [CIs]) of individual malignancies with exposure in the primary analysis for exposure to methotrexate within 12 months (A), exposure to tumor necrosis factor-α inhibitors (TNF-α) within 12 months (B), and exposure to ustekinumab within 12 months (C).*The P value comparing lung cancer cases with matched controls was significant for TNF-α inhibitor treatment (P = .028). Journal of the American Academy of Dermatology 2017 77, 845-854.e5DOI: (10.1016/j.jaad.2017.07.013) Copyright © 2017 American Academy of Dermatology, Inc. Terms and Conditions